D
Diane Bringman
Researcher at MetroHealth
Publications - 7
Citations - 595
Diane Bringman is an academic researcher from MetroHealth. The author has contributed to research in topics: Fatty liver & Steatohepatitis. The author has an hindex of 5, co-authored 7 publications receiving 538 citations.
Papers
More filters
Journal ArticleDOI
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network
Elizabeth M. Brunt,David E. Kleiner,Laura Wilson,Aynur Unalp,Cynthia E. Behling,Joel E. Lavine,Brent A. Neuschwander-Tetri,Stephanie H. Abrams,Diana Arceo,Denise Espinosa,Leanel Fairly,Diane Bringman,Carol Hawkins,Yao Chang Liu,Nicholette Rogers,Margaret Stager,Arthur J. McCullough,Srinivasan Dasarathy,Kevin Edwards,Ruth Sargent,Melissa J. Coffey,Karen F. Murray,Melissa Young,Parvathi Mohan,Kavita Nair,Manal F. Abdelmalek,Anna Mae Diehl,Marcia R. Gottfried,Cynthia D. Guy,Paul G. Killenberg,Samantha Kwan,Yi Ping Pan,Dawn Piercy,Melissa Smith,Prajakta Bhimalli,Naga Chalasani,Oscar W. Cummings,Lydia Lee,Linda Ragozzino,Raj Vuppalanchi,Barbara Calabrese,Debra Peglow,Ann O. Scheimann,Michael Torbenson,Ann Klipsch,Jean P. Molleston,Girish Subbarao,Sarah E. Barlow,Jose Derdoy,Joyce Hoffmann,Debra King,Joan Siegner,Susan Stewart,Brent A. Tetri,Judy Thompson,Cynthia Behling,Manual Celedon,Lisa Clark,Janis Durelle,Tarek Hassanein,Susana Mendoza,Jeffrey B. Schwimmer,Claude B. Sirlin,Tanya Stein,Allison Tobin,Kiran Bambha,Nathan M. Bass,Linda D. Ferrell,Danuta Filipowski,Raphael B. Merriman,Mark Pabst,Monique Rosenthal,Philip J. Rosenthal,Tessa Steel,Sherry Boyett,Daphne Bryan,Melissa J. Contos,Michael Fuchs,Martin F. Graham,Amy Jones,Velimir A. Luketic,Bimalijit Sandhu,Arun J. Sanyal,Carol Sargeant,Kimberly Selph,Melanie B. White,Kris V. Kowdley,Grace Gyurkey,Jody Mooney,James E. Nelson,Sarah Roberts,Cheryl Saunders,Alice Stead,Chia Wang,Matthew M. Yeh,Elizabeth M. Brunt,D Kleiner,Gilman D. Grave,Terry T.-K. Huang,Edward Doo,Jay E. Everhart,Jay H. Hoofnagle,Patricia R. Robuck,Leonard B. Seeff,Patricia Belt,Fred Brancati,Jeanne M. Clark,Ryan Colvin,Michel Donithan,Mika Green,Rosemary Hollick,Milana Isaacson,Wana Kim,Alison Lyndecker,Laura Miriel,Alice L. Sternberg,James Tonascia,Aynur Unalp-Arida,Mark L. Van Natta,Laura A. Wilson,Katherine P. Yates +120 more
TL;DR: Increased portal CI is associated with many clinical and pathologic features of progressive NAFLD in both adults and children, but not with ALT, autoantibodies, or lobular inflammation.
Journal ArticleDOI
Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network.
Kristin David,Kris V. Kowdley,Aynur Unalp,Fasiha Kanwal,Elizabeth M. Brunt,Jeffrey B. Schwimmer,Jeffrey B. Schwimmer,Stephanie H. Abrams,Diana Arceo,Denise Espinosa,Leanel Fairly,Arthur J. McCullough,Arthur J. McCullough,Diane Bringman,Srinivasan Dasarathy,Srinivasan Dasarathy,Carol Hawkins,Yao Chang Liu,Nicholette Rogers,Margaret Stager,Kevin Edwards,Ruth Sargent,Melissa J. Coffey,Karen F. Murray,Melissa Young,Parvathi Mohan,Kavita Nair,Anna Mae Diehl,Marcia Gortfried,Cynthia D. Guy,Paul G. Killenberg,Samantha Kwan,Yi Ping Pan,Dawn Piercy,Melissa Smith,Prajakta Bhimalli,Naga Chalasani,Oscar W. Cummings,Lydia Lee,Linda Ragozzino,Raj Vuppalanchi,Ann O. Scheimann,Michael Torbenson,Ann Klipsch,Jean P. Molleston,Girish Subbarao,Sarah E. Barlow,Jose Derdoy,Joyce Hoffmann,Debra King,Joan Siegner,Susan Stewart,Brent A. Tetri,Judy Thompson,Cynthia Behling,Manual Celedon,Lisa Clark,Janis Durelle,Tarek Hassanein,Joel E. Lavine,Susana Mendoza,Claude B. Sirlin,Tanya Stein,Allison Tobin,Kiran Bambha,Nathan M. Bass,Linda D. Ferrell,Danuta Filipowski,Raphael B. Merriman,Mark Pabst,Monique Rosenthal,Philip J. Rosenthal,Tessa Steel,Sherry Boyett,Daphne Bryan,Melissa J. Contos,Michael Fuchs,Martin F. Graham,Amy Jones,Velimir A. Luketic,Bimalijit Sandhu,Arun J. Sanyal,Carol Sargeant,Kimberly Selph,Melanie B. White,Grace Gyurkey,Jody Mooney,James E. Nelson,Sarah Roberts,Cheryl Saunders,Alice Stead,Chia Wang,Matthew M. Yeh,Elizabeth M. Brunt,David E. Kleiner,Gilman D. Grave,Terry T.-K. Huang,Edward Doo,James E. Everhart,Jay H. Hoofnagle,Patricia R. Robuck,Leonard B. Seeff,Patricia Belt,Fred Brancati,Jeanne M. Clark,Ryan Colvin,Michele Donithan,Mika Green,Rosemary Hollick,Milana Isaacson,Wana Kim,Alison Lydecker,Laura Miriel,Alice L. Sternberg,James Tonascia,Mark L. Van Natta,Laura A. Wilson,Katherine P. Yates +117 more
TL;DR: Treatment of NAFLD should incorporate strategies to improve QOL, especially physical health, and Cirrhosis was associated with poorer physical health after adjusting for potential confounders.
Journal ArticleDOI
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C
Zobair M. Younossi,Arthur J. McCullough,Janus P. Ong,David S. Barnes,Anthony B. Post,Anthony S. Tavill,Diane Bringman,Lisa M. Martin,Jennifer Assmann,Terry Gramlich,Kevin D. Mullen,Robert O'Shea,William D. Carey,Roy Ferguson +13 more
TL;DR: Higher grade of steatosis and presence of superimposed NASH are both associated with advanced hepatic fibrosis and markers of obesity (BMI and W/H) and HCV genotype 3 are associated with the extent of ste atosis and type of fatty liver.
Journal ArticleDOI
Pegylated Interferon α-2b, ribavirin and amantadine for chronic hepatitis C
Zobair M. Younossi,Arthur C. McCullough,David S. Barnes,Anthony B. Post,Janus P. Ong,Robert O'Shea,Lisa M. Martin,Diane Bringman,Denise W. Farmer,Gavin Levinthal,Kevin D. Mullen,William D. Carey,Anthony S Tavill,Anthony S Tavill,Roy Ferguson,Terry Gramlich +15 more
TL;DR: The addition of amantadine to pegylated interferon α-2b and ribavirin does not seem to increase the efficacy of this antiviral regimen.
Journal ArticleDOI
Triple combination of interferon a-2b, ribavirin, and amantadine for treatment of chronic hepatitis C
Zobair M. Younossi,Kevin D. Mullen,Sandra Hodnick,Marilyn McCormick,Diane Bringman,David S. Barnes,William D. Carey,Arthur J. McCullough,Kirk A Easley,Belinda Yen-Lieberman +9 more
TL;DR: In thisinterferon‐resistant group, a treatment regimen of interferon alpha‐2b, ribavirin, and amantadine was associated with only a 10% sustained viral eradication rate, which was sustained 6 months after the discontinuation of treatment.